Member Info for Wigwammer

Bye bye beancounter. I don’t mind paying taxes at all, just subsidising self inflated ineffective whingers.. ATB

When the shares go up they are wise shareholders. When the shares go down “they told you so”. Unfortunately as a British taxpayer I have to subsidise these posturing commentators

I really can’t understand these posters who own the shares, but appear entirely bewildered by anyone suggesting something positive might happen. The posturing never ends..

You make some good points, pokerchips. From the current low valuation there is plenty of potential for positive rerating in the event we get patent extension, partnerships and eventually (hopefully) trial news. And if management get there they will have done an excellent job, because they are a small company operating in a complex sector, and there is very little appetite currently to fund small cap biotechs. If it doesn’t happen, c’est la vie. It’s a high risk/high reward play and so investors should only bet an appropriate amount. As stated on Friday, the alternative plans suggested by the sceptics amount to little more than hot air. Silly rhetoric. Fulfilling a need to blame someone else, when they evidently didn’t buy the shares with their eyes open.. GLA DYOR etc

Lol oldbut. That 7p sell was trade of the year. Well done. GLA etc

Which of our illustrious shareholders would you invite to this bargain basement capital markets day, scrodingers? Perhaps Lanstead? The rest of the market is not interested. That is true for most of the small cap U.K. biotech sector. So thank you for your plan - some nice rhetoric that will appeal to the wolves - but nothing of any substance… In the meantime, I suggest IMM patent their technology around the new research, and try again to get a deal. Which is sort of what they’re doing. Good weekend all

Scrodingers - yes I’m sure there is a large raft of holders underwater here, including you and me. You are no less naive than the next man, I’m afraid. And it is not so much that I defend Tim, as that I choose not to attack him. Because it may well be he is working hard, but faces a steep uphill struggle - because he is trying to progress a small biotech company with very limited funds in a world disinterested in small biotech companies… Your “alternative strategies” are naive IMO - capital market days and specialist dealmakers are expensive. The capital markets are not interested currently. All that would happen is the money would run out faster. None of your ideas address the core issue - that at least until very recently, the pace of development of the science has been glacial. And Tim is not a scientist. While I’m sure it’s easier for some (especially those with simply superb business acumen) to attack management or other investors, the plain reality is that we all backed the science, and perhaps too early. Oh no - pointing the finger at the person who actually bought the shares. How frightening for you! I suspect if the business had been managed by an accountant with a penchant for capital market days and specialist dealmakers, the shares would have sunk to zero many moons ago. Have a lovely weekend.

No offence taken, scrodingers. You own the shares and they have gone down a lot. On that basis, I don’t think many should take advice from you. Furthermore, you believe there is a less than 50:50 chance of success, yet continue to believe it is logical to hold. Perfect reasoning I’m sure. It is perfectly reasonable to question management of course, but one needs to be objective and balanced. TM was part of the management team that got p140 to ph3 trial result in 2018. On that occasion it failed, but he is not a scientist. He has kept the story afloat despite glacial development on the science side (at least until very recently). So perhaps you could enlighten us as to what you would have done differently? Why didn’t you go to the AGM and enlighten TM too? (I’m afraid ticking a box on a form is a bit of a cop out). Why do you continue to hold a stock when you have so little positive to say about it? No sense in pointing the finger at supposed naive people here, nobody here bought your shares for you… GLA etc

Just put him on filter and don’t give it oxygen.. GLA

But it is all just endless posturing on this board. Many of the sceptics continue to hold their shares. Why? Presumably because they are hoping - just like every holder here - that the shares are going to rise. The sceptics try to portray another breed of holder - more naive than themselves - that they can throw sticks at. But in terms of action they do nothing different. In fact, most of these sceptics were naive enough to buy far earlier and at a higher price than the “hopefuls” they currently attack. All holders are hoping and waiting for positive news. The sceptical posturing by certain holders just tells you more about the poser than about immupharma. GLA DYOR etc

I see spanny. So either you’re sitting on massive losses, or what you say and what you do are totally different things. Such an invaluable poster :)

No assumptions, spanny. You said you bought at a massive premium to where we are now, and the shares have consequently nosedived. Top end stuff :)

No need to guess, spanny. Either you’re sitting on a massive capital loss or you’ve locked one in. Market having a good chuckle at you either way :)

On 8th July spantripe wrote “ Wig I have tranches at 4.4, 3.36, 2.61 and 2.35 “… Perhaps he has since locked in his massive loss. Ouch.

No I rather think you may be going senile, spanny. Because you bought the shares at some massive premium to where we are now, yet you appear entirely oblivious as to why you own them. What price did you pay again?

Jolly good. So a few of the sceptics are now expecting a deal. What this change in view has to do with today’s RNS I’m not sure, but I welcome it anyway. GLA DYOR etc

Remind us what price you paid again, spanny :)

Makemore - only the upfront part of a deal would be paid in immediate cash. So in the context of a $1bn deal, only perhaps $50m would likely be an upfront cash payment. The rest would only be paid in the event that p140 hits certain development and sales milestones. So the suitor benefits because they do not have to pay out large sums upfront and take on a large financial risk that the drug does not progress, as they would have to do if purchasing the whole company. If immupharma gets patent protection and a decent partner then 10p+ (circa £65m+ fully diluted market cap) should be reached as a conservative estimate .. IMO DYOR etc

Let’s not forget lollywally is one of the biggest percentage losers here. His no nonsense fact based approach has simply worked wonders.. :)

From AI. Do Lanstead have to sell all their shares over the period of the sharing agreement?

“No, Lanstead is not required to sell all of their shares under a typical sharing agreement. While Lanstead will be issued shares and will pay for them, the number of shares is fixed. The amount they owe under the agreement is adjustable based on the company's share price over the agreement's period. Lanstead benefits from the share price increasing, but they are not obligated to sell their shares.

Lanstead is not forced to sell their shares. They can choose to sell or hold their shares, just like any other shareholder. ”